ArticleClinical rheumatology2007
Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis.
Article in Clinical rheumatology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Review
- Interactions among glomerulus infiltrating macrophages and intrinsic cells via cytokines in chronic lupus glomerulonephritis.Journal of autoimmunity · 2020Article
- Intracapillary immune complexes recruit and activate slan-expressing CD16+ monocytes in human lupus nephritis.JCI insight · 2018Article
- Automated detection of off-label drug use.PloS one · 2014Article
- Monoclonal Antibodies for Systemic Lupus Erythematosus (SLE).Pharmaceuticals (Basel, Switzerland) · 2010Review
- Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances.Journal of biomedicine & biotechnology · 2010Review
- The role of tumor necrosis factor-alpha in systemic lupus erythematosus.Arthritis research & therapy · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Because disease activity in systemic lupus erythematosus correlates well with increased serum levels and activity of the cytokine tumor necrosis factor alpha (TNF-alpha), we report on the safety and efficacy of infliximab, a chimeric monoclonal antibody directed against TNF-alpha, given to a patient with active lupus with diffuse proliferative nephritis (WHO Class IV). This patient who failed to remit with a combination of full-dose steroids, mycophenolate mofetil, and cyclosporine, went into sustained remission with the addition of infliximab infusions.
Indexed as
Identifiers
16565897What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.